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Title of study: A phase 3, placebo controlled, randomized, double-blind study to 
evaluate the efficacy and safety of Infliximab (INF)for the treatment of moderate to 
severe Hidradenitis Suppurativa (HS). 
Study phase: 3 
Investigational product: Infliximab 
Research Hypothesis: We assessed the efficacy and safety of infliximab (IFX) for the 
treatment of moderate to severe HS 
Primary Efficacy Objective: The primary objective of this study is to evaluate the 
effectiveness of Infliximab (INF) for the treatment of moderate to severe 




Hidradenitis suppurativa / acne inversa (HS) is a chronic, inflammatory, recurrent, 
debilitating skin disease of the hair follicle that usually presents after puberty with 
painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the 
body, most commonly the axillae, inguinal and anogenital regions (Dessau definition, 
1st International Conference on Hidradenitis suppurativa/Acne inversa, March 30-
April 1, 2006, Dessau, Germany) 
Definition: Hidradenitis suppurativa / acne inversa (HS) is a chronic, inflammatory, 
recurrent, debilitating skin disease of the hair follicle that usually presents after 
puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing 
areas of the body, most commonly the axillae, inguinal and anogenital regions .  
 Clinical presentation Recurrent inflammation occurring more than 2x/6 months or 
3x/6 months in the inverse regions of the body, presenting with nodules, sinus-tracts 
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Primary positive diagnostic criteria  
History: Recurrent painful or suppurating lesions more than 2x/6 months. Signs: 
Involvement of axilla, genitofemoral area, perineum, gluteal area and infra-
mammary area of women. Presence of nodules (inflamed or non-inflamed). sinus 
tracts (inflamed or noninflamed), abscesses, scarring (atrophic, mesh-like, red, 
hypertrophic or linear). 
 Secondary positive diagnostic criteria  
History: Family history of HS.  
Microbiology: A negative swab or the presence of normal skin microbiota may be 
indicative of HS. 
 Differential diagnosis 
 • Staphylococcal infection (lesions are spread in a random fashion and more 
pustular)  
• Cutaneous Crohn’s disease (associated intestinal Crohn's disease)  
• Simple abscesses (usually single lesions)  
• Neoplasms, primary or secondary (systemic and histological signs of tumor)  
• Lymphogranuloma venereum 
 • Rare: 
 o Cutaneous actinomycosis (presents with sinus tract disease)  
o Scrofuloderma type of cutaneous tuberculosis 
 Classification and severity assessment 
 Hurley staging  
In 1989, a severity classification was first proposed by Hurley (4).  
 
• Stage I: Abscess formation, single or multiple, without sinus tracts and 
cicatrisation.  
• Stage II: Recurrent abscesses with tract formation and cicatrisation, single or 
multiple, widely separated lesions.  
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• Stage III: Diffuse or near-diffuse involvement, or multiple interconnected tracts and 
abscesses across the entire area.  
Stage I disease is most common (68% of patients), while stage II occurs in 28% of 
patients, and 4% of HS patients have stage III . Today, the Hurley classification is still 
useful for the classification of three severity groups but the classification has 
limitations. The Hurley classification is not quantitative, consisting of only 3 stages 
and based on static disease characteristics such as scarring and fistulas. Hence, it is 
not suitable for monitoring the efficacy of interventions in clinical trials.  
Sartorius score 
 A more detailed and dynamic HS severity score was created by Sartorius et al. and 
was later modified . The main parameter in the modified Sartorius score is the 
counting of individual nodules and fistulas. The modified Sartorius score was the first 
disease specific instrument for dynamically measuring clinical severity. However, it 
has been argued that its usability is limited in severe cases in which separate lesions 
become confluent. Even if this score is more dynamic than the Hurley score it still 
includes lesions, which may not be sensitive to medical treatment (scars; distance 
between two relevant lesions). 
 Physician global assessment (PGA) 
 Currently, a PGA is the most frequently used assessment tool to measure clinical 
improvement in clinical trials of medical treatments. A recently developed six stage 
PGA was defined as follows: 
• Clear: no inflammatory or non-inflammatory nodules  
• Minimal: Only the presence of non-inflammatory nodules 5  
• Mild: Less than 5 inflammatory nodules or 1 abscess or draining fistula and no 
inflammatory nodules  
• Moderate: Less than 5 inflammatory nodules or one abscess or draining fistula and 
one or more inflammatory nodules or 2–5 abscesses or draining fistulas and less 
than ten inflammatory nodules 
 • Severe: 2–5 abscesses or draining fistulas and ten or more inflammatory nodules 
 • Very severe: More than 5 abscesses or draining fistulas  
 Epidemiology 
 Prevalence and incidence 
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 Several studies aimed to assess frequency of HS using prevalence or incidence 
estimations in different settings (hospital versus population-based), different time 
periods (from 1968 to 2008) different diagnosis methods (self-reported, medically 
assessed, diagnosis of treatments codes through automated requests in medical 
information systems) leading to an important variability of estimations and 
uncertainties regarding the actual frequency of HS . One recent study estimated the 
incidence of HS in an American county (Minnesota) with a population of about 
144,000 people. The source was the Rochester Epidemiologic Project, a medical 
information system gathering records from hospitals, clinics, private practitioners 
and nursing homes within the county. Between 1968 and 2008, 268 HS cases were 
identified leading to a mean incidence of 6.0 per 100,000 person-years with a two-
fold incidence between the extremities of the period (4 to 10 per 100,000 person-
years). This increase may be due to an increase in detection and coding of HS in the 
medical information system. The strength of this study was to estimate the incidence 
of HS for the first time. The limit of the study was its retrospective design. Moreover, 
there may be a selection bias due to recruitment through medical 6 information 
system leading to a possible under estimation of incidence. There also may be a 
classification bias due to missed diagnosis of mild early cases. 
 By postulating a duration of active HS being a maximum of about 20 years for a 
given subject, the incidence can be extrapolated to prevalence = incidence x 
duration of the disease. Accordingly, the prevalence would be:  
• Max: 10/100,000 years x 20 years = 200/100,000 = 0.20% 
 • Min: 4/100,000 years x 20 years = 80/100,000 = 0.08%. 
 This conclusion is supported by expert opinion.  
 Psychosocial impact 
 The skin is a very important organ for our proper psychosocial functioning, as it is 
the largest and most visible part of the body. It plays a crucial role in interpersonal 
relationships, self-esteem, and perception of self-image and public image. 
Undoubtedly, HS due to its character has a huge impact on patients’ quality of life 
(QoL). Therefore, many HS sufferers have to deal with depression and 
embarrassment. In addition, fever and fatigue often arise in extreme cases and may 
prevent individuals from performing even common everyday-tasks. 
 Pain  
One of the most important problems reported by HS patients is pain, usually linked 
to the deep seated inflammatory nodules. Patients describe it in many ways, e.g. as 
hot, burning, pressing, stretching, cutting, sharp, taut, splitting, gnawing, sore, 
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throbbing or aching. HS patients rated their pain using a Visual Analog Scale (VAS) as 
4.5 ± 2.4 points (range, 0-10 points) or by means of a Numeric Rating Scale-11 (NRS) 
as 3.6 ± 3.2. Moreover, when compared to other dermatological conditions, which 
served as a control, the difference of pain intensity was of significant importance 
(p<0.001). 
Dermatology Life Quality Index  
The influence of HS on patients’ Quality of Life was quite often evaluated with a 
population-specific questionnaire - Dermatology Life Quality Index (DLQI). Even 
though the data is still limited, the observations are consistent and convergent . All 
of the DLQI subdomains were “hardly” affected, but the greatest impact was 
reported for ‘symptoms and feelings’ and ‘daily activities’. HS’s  impact on QoL is 
estimated as having large or extremely large effect on patient's life for nearly 60% of 
examined patients . The main predictors of QoL impairment were HS clinical stage 
assessed accordingly to Hurley classification (p<0.0001) number of skin areas 
involved by HS lesions (R=0.28; p=0.045) and anogenital localization (p=0.0051). 
Similar findings were revealed in a study by Onderdijk et al. , where patients with 
more severe disease (with reference to Hurley staging or number of flares during the 
last month) had markedly higher DLQI scores. (p<0.05) 
It can be concluded that HS is a highly distressing disease for many patients, 
probably one of the worst that has been analyzed and evaluated in dermatology to 
date. 
Descriptive studies have shown a positive correlation between disease severity and 
BMI and tobacco smoking. Although no data exist for improvement of HS lesions 
after reduction of weight and cessation of tobacco smoking, the general expert 
opinion is that cigarette smoking and overweight have to be avoided. 
Generally, HS affects patients' lives in many ways. The sufferers underline the 
problems linked to interpersonal contacts, especially in relation to appearance and 
smell, various emotional reactions, as well as feelings of lack of control. HS has a 
great emotional influence on patients and promotes the social isolation. Irritation 
and shame are frequent and relate to smell, pain, scars, and itching. Moreover, not 
surprisingly, such a chronic and debilitating skin disease has its reflection in socio-
economic status tightly related to professional activity. The studies underline the 
significant work disability rate together with high unemployment rate among HS 
sufferers, while most of them are in a productive age. 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:07:35 EET - 137.108.70.7
MASTER THESIS ΔΑΛΑΜΠΟΥΡΑ ΔΕΣΠΟΙΝΑ Σελίδα 8 
 
Treatments with Biologics 
According to current evidence adalimumab and infliximab are effective in the 
treatment of moderate to severe HS and improve the quality of patient life, with 
adalimumab more tolerable. 
Adalimumab  
Mechanism: Adalimumab is a fully human therapeutic monoclonal antibody. It 
corresponds to the human immunoglobulin IgG1 and has heavy and light chain 
variable regions exhibiting specificity for human TNF-α. Adalimumab binds with high 
affinity and specificity to soluble and membranebound TNF-α. Thus the binding to 
the TNF-α receptor is prevented (p55 and p75) and blocks the biological effect of 
TNF-α. 
Dosage and duration of treatment: 
 • a) To condition for a curative surgical procedure: adalimumab 160 mg on day zero 
and possibly 80 mg one week later. 
 b) For long-term therapy: adalimumab 40 mg once weekly . 
 • Adalimumab is administered by subcutaneous injection.  
• There is no dose adjustment for patients with obesity (> 100 kg).  
Response rate: There are different rates of response to adalimumab reported in case 
series and in a current, prospective controlled study. 
 Administration of adalimumab with a cumulative response rate of 58% 
(improvement ≥50% in 23 patients) has been reported in case reports with 42 
patients with moderate to severe HS (10,103- 106) (Table 3). In a prospective, open 
study with 15 patients with moderate-to-severe HS, medium-term treatment (3 
months) with adalimumab resulted in significant reduction of Sartorius score by 
week 24 with a marked improvement during the first month (107) . VAS score and 
DLQI showed a significant decrease at week 24. In another prospective, open study 
with 6 patients with moderate to severe HS, medium-term treatment (3 months) 
with adalimumab failed to reduce HSSI score in any of the patients at week 2, 4, 8, 
and 12 (10) . VAS and DLQI scores also failed to show statistically significant 
improvement. 
Follow-up investigations: Relapses after discontinuation of treatment and/or 
surgery required was reported in 10 of 14 among the case reports patients (71%). 
Relapses after discontinuation were also reported in the patients group reported. A 
decrease in response was seen after the switch from adalimumab weekly to every 
other day dosing in an open follow-up study at weeks 16 to 52.  
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Complications: Under adalimumab treatment tolerance was satisfactory . In the 
placebo-controlled studies reaction at the injection site was the most commonly 
reported adverse drug reaction (adalimumab: 20% of patients, placebo: 14%). No 
major adverse events could be observed. Under adalimumab therapy increased 
infections may occur, especially at the upper respiratory tract, bronchitis and urinary 
tract infections. Reported serious infections are pneumonia, septic arthritis, post-
operative infections, erysipelas, diverticulitis, and pyelonephritis. Autoantibodies 
(ANA, anti-dsDNA antibodies) can be induced; a rare "lupus-like syndrome" was 
described. Very rarely, malignancies, especially lymphomas occur. 
Women should receive contraception up to five months after the last dose of 
adalimumab. Should pregnancy be diagnosed under adalimumab treatment, it 
should be discontinued. Damage to the child cannot be expected due to lack of 
embryo or fetal toxicity (FDA classification B). During lactation Adalimumab is 
contraindicated due to the potential transition into the milk. 
 
Infliximab 
 Mechanism: Infliximab is a chimeric (mouse / human) monoclonal antibody against 
TNF-α. It is an IgG1 immunoglobulin with human sequences in the constant regions 
and murine sequences in the complementarity-determining regions of the light and 
heavy chains. It binds specifically to both soluble and transmembrane, receptor-
bound TNF-α. Soluble TNF-α is ligated and its proinflammatory activity is neutralized. 
Moreover, binding to cell membrane-bound TNF-α leads to an elimination of the 
affected cells, possibly due to complement activation and / or antibodydependent 
cellular cytotoxicity, but also due to induction of apoptosis. Infliximab has a serum 
halflife of about 8 to 9.5 days. The elimination period is up to 6 months. 
Dosage and duration of treatment: 
• To condition for a curative surgical procedure: Infliximab 5 mg / kg body weight 
may be used. 
• For long-term therapy: infliximab 5 mg / kg body weight on day zero, two, six 
and then regularly every eight weeks.  
• With longer intervals between infusions, the probability of the formation of 
infliximab antibodies increases.  
• Infliximab is administered intravenously over a period of two hours. If no infusion 
reactions occur, it can also be given over one hour. During the infusion and for one 
hour after it monitoring of patients for infusion reactions is necessary. 
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Response rate: Administration of infliximab with a cumulative response rate of 58% 
(improvement ≥50% in 42 patients) has been reported in case reports with 73 
patients with moderate to severe HS. In a prospective, randomized, double-blind, 
placebo-controlled, cross-over study of infliximab treatment (5 mg/kg iv at weeks 0, 
2, 6) of 33 patients with HS for 2 months no significant difference in the >50% 
improvement was detected (primary end point), while a significantly higher 25-50% 
improvement rate was detected under infliximab (27% vs. 5% under placebo). In a 
retrospective comparative (1:1) study with 20 patients, a significantly greater 
reduction was detected for infliximab (5 mg / kg iv at weeks 0, 2 and 6) in mean 
Sartorius score (56%) in comparison with adalimumab (40 mg sc every other week) 
(34%). 
 Follow-up investigations: Long-term treatment (1 year) of 8 patients with 
moderate-to-severe HS with infliximab resulted in significant reduction of the 
number of involved sites and flares. . In a further study with long-term treatment (4 
years) of 10 patients with moderate-to-severe HS with infliximab 80% responses 
were reported. Response (≥50%) occurred after 3 to 7 drug administrations (13 to 45 
weeks). Four of 8 patients relapsed despite treatment (after 6 administrations). 
Moreover, recurrences after discontinuation of treatment and/or surgery required 
was reported in 15 of 35 among the case reports patients (43%). 
Complications: The long-term tolerance (n=8 patients, 1 year) was satisfactory with 
only 4 minor infections, 1 keratoacanthoma and one case of rapidly resolving 
hepatitis. In a retrospective 33 comparative study on the safety of infliximab and 
adalimumab in 5 of 27 patients (18%) who were treated for an average of 12 months 
with infliximab a polyarthritis was detected, which healed spontaneously 4 months 
after discontinuation of infliximab . This side effect was not observed under 
adalimumab treatment. There are extensive data on the safety of treatment with 
infliximab in inflammatory bowel disease, arthritis and psoriasis vulgaris. Acute 
infusion reactions with mild chills, headache, flushing, nausea, dyspnea or infiltration 
at the infusion site are common. The likelihood of an infusion reaction is higher in 
patients with infliximab-specific antibodies. Anaphylactoid reactions, regardless of 
whether infliximab-specific antibodies are present, can occur. Retreatment after 
longer treatment periods may induce arthralgia, myalgia and angioedema. A 
moderate infusion reaction can be prevented or attenuated by prior administration 
of antihistaminics or even prevented. By the addition of low-dose methotrexate (5-
10 mg / week), the formation of antibodies to infliximab can be reduced. Infections, 
worsening of heart failure, demyelinating diseases, hepatotoxicity, leukopenia, 
neutropenia, thrombocytopenia or pancytopenia lupus erythematosus-like 
syndrome may also occur. 
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Other TNF-α inhibitors  
Treatment of patients with HS with etanercept has also been reported in case 
reports and a clinical study. 
 Mechanisms: Etanercept is a fusion recombinant protein, which fuses the TNF 
receptor and interferes with TNF-α. 
 Response rate: Administration of etanercept (25 mg sc twice weekly over 3-10 
months) with a cumulative response rate of 44% (improvement ≥50% in 15 patients) 
has been reported in case reports with 34 patients with moderate to severe HS. 
Relapses after discontinuation of treatment occurred in 10 of 14 patients (71%). In a 
prospective, randomized, double-blind, placebo-controlled, cross-over study of 
etanercept treatment (50 mg sc twice weekly) of 20 patients with HS for 3 months 
no difference compared with placebo could be detected. 
Other Biologicals 
 Treatment of patients with HS with ustekinumab has also been reported in case 
reports Administration of ustekinumab (three 45 mg sc injections on weeks 0, 4 and 
16) with a cumulative response rate of 33% (improvement ≥50% in 1 patient) has 
been reported in a case series of 3 patients with moderate to severe HS. Relapses 




Biologic therapies with anti-tumor necrosis factor agents are promising treatments 
for hidradenitis suppurativa (HS).  
Objective: To assess the efficacy and safety of infliximab (IFX) for the treatment of 
moderate to severe HS 
This is a randomized, double-blind treatment phase of 8 week where patients 
received IFX or placebo was followed by an observational phase.  
Primary treatment efficacy will be based on HS Severity Index.  
Secondary end points included Dermatology Life Quality Index, visual analog scale, 
and Physician Global Assessment scores. Inflammatory markers erythrocyte 
sedimentation rate and C-reactive protein were also assessed. 
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The EC consists of members of the academic leadership of the study and one 
member from the sponsoring company. The EC will ultimately be responsible for the 
conduct of the study including addressing any Data Monitoring Committee 
recommendations and overseeing publication of the results. 
Steering Committee 
A Steering Committee will be formed consisting of members who are lead 
investigators from each country/region. The Steering Committee will advise and 
assist the EC with regard to the scientific and operation aspects of the  study. 
Independent Data Monitoring Committee 
This study will be conducted under the auspices of an independent Data Monitoring 
Committee (DMC), which will monitor the progress of the study and ensure that the 
safety subjects enrolled in the study is not compromised. The DMC will have a 
chairperson and include at least 2 dermatologists, as well as a statistician. This 
committee will review accumulating data on a regular basis, and may request to 
review partially unblended accumulating data. The DMC will make recommendations 
to the Executive Committee and Sponsor regarding the continuing safety of subjects 
currently enrolled and yet to be enrolled in the trial. At all times during the course of 
the study, the DMC may request access to the unblended data if needed.  
Clinical Endpoint Committee 
The Clinical Endpoint Committee (CEC), composed of experts in the relevant fields, 
will  review, in a blinded manner, all reported study outcomes to provide consistency 
and validity in the assessment of outcomes. Their decisions will be based on blind 
clinical data. Theirs decisions will be used for the final statistical analyses. 
 
ETHICAL CONSIDERATIONS 
This study will be conducted in accordance with Good Clinical Practice (GCP). Good 
Clinical Practice is an international ethical and scientific quality standard for 
designing, conducting, recording, and reporting research studies that involve the 
participation of human subjects. Compliance with this standard provides public 
assurance that the rights, safety and well-being of study subjects are protected, 
consistent with the principles that have their origin in the Declaration of Helsinki, 
and that the clinical study data are credible.  
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INDEPENDENT ETHICS COMMITTEE 
Τhe protocol and any amendments, the Investigator’s Brochure, the subject 
informed consent and any information on compensation for study-related injuries or 
payment to subjects, will receive IRB/IEC approval prior to initiation of the study. 
During the study the investigator will send to the IRB any reports of adverse events 
that are serious, unlisted, and associated with the investigational drug and any new 
information that may adversely affect the safety of the subjects or the conduct of 
the study. The personnel involved in this study will be qualified by education, 
training and experience to perform their respective task. 
INFORMED CONSENT 
It is the investigators’ responsibility to ensure that subjects, are legally acceptable 
representatives, are clearly and fully informed about the aims, methods, anticipated 
benefits, potential risks, and other critical issues regarding clinical studies in which 
they volunteer to participate. 
The written ICF should be prepared in the local language of the potential study 
population. The informed consent should be approved by the responsible IB in 
advance of use. 
Subjects unable to give their written consent may only be enrolled in the study with 
the consent of a legally acceptable representative. The subject must also be 
informed about the nature of the study to the extent compatible with the subject’s 
understanding. If the subject or a subject’s legally acceptable representative is 
unable to read, an impartial witness should be present during the entire informed 
consent discussion.  
In order to successfully maintain the safety objectives of this endpoint driven trial, it 
is essential that each subject’s follow-up and vital status be maintained through the 
end of the study. All reasonable efforts must be made to locate subjects to 
determine and report their current and ongoing status. The rights, safety, and well-
being of the study subjects are the most important considerations and should prevail 
over interests of both science and society.  
SUBJECT CONFIDENTIALITY 
 The investigators and the Sponsor will preserve the confidentiality of all subjects 
taking part in the study, in accordance with GCP and local regulations. 
The investigator must ensure that the subject’s anonymity is maintained. On the 
eCRFs or other documents submitted to the Sponsor of the CRO, subjects should be 
identified by a unique subject identifier as designated by the Sponsor. Sponsor 
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personnel whose responsibilities require access to personal data should agree to 
keep the identity of study subjects confidential. 
 
SELECTION OF SUBJECTS- STUDY POPULATION 
Τhe study population will  consist of adult subjects with moderate to severe 
Hidradenitis Suppurativa (HS). 
 
INCLUSION CRITERIA 
For entry into the study, the following criteria MUST be met: 
1) Age > 18 years 
2) A clinical diagnosis of moderate to severe HS defined as Hurley II or Hurley III 
for at least 6 months, where: 
Hurley II: Recurrent abscesses, single or multiple widely separated lesion, with 
sinus track formation. (Frequent inflammation restricts movement and may 
require minor surgery such as incision and drainage) 
Hurley III: Diffuse or broad involvement across a regional area with multiple 
interconnected sinus tracts and abscesses. (Inflammation of sites to the size of 
golf balls, or sometimes baseballs; scarring develops, including subcutaneous 
tracts of infection.  
Obviously, patients at this stage may be unable to function.  
Male or female patients older than 18 years included in the trial had moderate to 
severe HS as defined by a HS Severity Index (HSSI) score greater than 8. HSSI is a 
composite score ranging from 0 to 19. The score was  
 obtained by assessing the number of sites involved,  
 percent of body surface involved (the palm of the hand was used to 
represent 1% of body surface area), 
 number of erythematous and painful lesions,  
 Number of dressing changes during working and leisure hours (which 
reflects interference in daily activities),  
 pain as quantified by the visual analog scale (VAS).  
HSSI was used to ascertain the activity and severity of HS in patients. 
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 In addition to the HSSI score greater than 8, patients had at least one of 
the following: (1) HS duration for longer than 1 year with multiple 
emergency department or doctor visits related to HS 
  Intralesional steroid injections of more than 5/year, however, none 
within 2 weeks of entry 
 failed systemic retinoid treatment, but not within 3 months of entry 
 Failed at least one prior course of antibiotic therapy, which must not 
have been administered within 2 weeks of entry to the study (excluding 
the recommended antibiotic regimen given immediately before 
randomization for active local or systemic infection) 
 History of reconstructive surgery, but not within 3 months of entry.  
Other inclusion criteria will be generally good health as assessed by blood 
laboratory tests, and w similar to those criteria for patients treated with IFX for 
other diseases. 
  
All subjects must provide signed written informed consent. 
EXCLUSION CRITERIA 
Potential subjects who meet any of the following criteria will be excluded from 
participating in the study: 
Pre treatment assessment: 
• Exclusion of acute infection. 
 • Exclusion of tuberculosis in accordance with current recommendations of 
the Paul Ehrlich Institute in Germany. 
 • HIV infection or viral hepatitis should be excluded with appropriate patient 
history, clinical and/or laboratory evidence. 
 • Pregnancy in women of childbearing age should be excluded and secure 
contraception. 
 • Patients should be advised that the course of infections could be more 
severe or atypical during treatment and that they have to early visit a 
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Contraindications:  
Absolute contraindications  
• Heart failure NYHA class III-IV  
• Known hypersensitivity to mouse proteins 
 • Pre-existing tuberculosis or other severe infections 
 • Pregnancy and lactation Important relative contraindications  
• Malignancies (except: basal cell carcinoma) and lymphoproliferative disorders as 
well as a history of malignancy  
• Vaccination with live vaccines 32 
 • Autoimmune diseases  
• Demyelinating processes 
 
Discontinuation of treatment- Withdrawal of Subjects 
Individual subjects may prematurely discontinue study drug. Reasons for study drug 
discontinuation are:  
 Safety concerns (e.g. adverse event, infections, worsening of heart failure, 
demyelinating diseases, hepatotoxicity, leukopenia, neutropenia, 
thrombocytopenia or pancytopenia lupus erythematosus-like syndrome). 
 Noncompliance of study drug 
 The need for an excluded concomitant medication 
A subject will be withdrawn from the study for any of the following reasons: 
 Withdrawal of informed consent form 
 Death 
 Lost to follow up 
In case a subject is lost-to-follow up, every possible effort must be made by the 
study site personnel to contact the subject to obtain complete data and determine 
the reason of withdrawal. This reason should be documented on the CRF and in the 
source document. 
Subjects, who discontinue treatment before the end of the study, and those who are 
withdrawn from the study, should have a follow-up visit approximately 30 days after 
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the study drug discontinuation visit and they will be contacted every 3 months until 
the study ends to assess efficacy endpoint events. 
 
 
RANDOMIZATION AND BLINDING 
Central randomization will be implemented in conducting this study. At the time of 
enrollment, each subject will be assigned a unique sequential subject number by the 
IVRS (interactive voice response system) and a treatment code, which will dictate the 
treatment assignment for the subject. The IVRS will be available 24 hours per day, 
seven days a week. The subject number will consist of a unique 5 digit number which 
is assigned sequentially within the study (starting with 00001) by the IVRS. This 
number will be used for identification throughout the study and will not be used for 
any other subject. Subjects will be randomly assigned in a 1:1 ratio (infliximab : 
placebo) to 1 and 2 treatment groups and the randomization will be stratified by 
country. So the IVRS will then also assign a medication kit (and subsequent 
medication kits) that matches the treatment code to which the subject has been 
randomized. 
The Investigator will not be provided with randomization codes. The codes will be 
maintained within the IVRS, which has the functionality to allow the Investigator to 
break the   blind for an individual subject. 
This study has a double-blind design. Neither the subjects nor any of the 
Investigators or Sponsor staff involved in the treatment or clinical evaluation of the 
subjects will be aware of the treatments received.  There will be an independent 
DMC to monitor the data in an unblended manner on a periodic basis. An 
independent statistician, not otherwise involved in the study, will prepare and 
provide the required reports to the DMC. 
The blind should be broken only if specific emergency treatment would be dictated 
by knowing the treatment status of the subject. If for any reason, the Investigator 
needs to become unblended to the treatment subject, he/she will make every 
attempt to first call the sponsor and discuss the need for unblinding and obtain 
agreement. If the Investigator is unable to contact the sponsor, the Investigator may 
in an emergency determine the identity of the treatment by telephoning IVRS. The 
sponsor must be informed as soon as possible by the investigator. Efforts should be 
made to limit access to knowledge of the treatment assignment to only those 
individuals who need to know the information and the subject should continue the 
study. 
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STUDY ASSESSMENTS AND PROCEDURES 
Procedures by Visit 
The study is divided into 3 periods: a screening period, a double-blind treatment 
period and a post-treatment observation period. All randomized subjects will be 
followed until the study ends, even if they did not take study drug or prematurely 
discontinued study drug. 
Screening period 
As part of study qualification which takes place before randomization, potential 
subjects will have the study risks and benefits explained to them, the associated ICF, 
reviewed with them, and all questions answered for them. Before the performance 
of any protocol-specific procedure, written informed consent should have been 
obtained by the investigator. 
Screening procedures will be performed within 15 days before randomization. 
 The investigator will: 
 obtain relevant medical history 
 obtain vital signs 
  perform physical examination 
 perform chest radiograph 
 obtain purified protein derivative skin test 
 obtain clinical assessment of disease activity and severity 
 obtain clinical chemistry and hematology, and serology for HIV, hepatitis B 




Eligible subjects will be randomized to study medication as described and study drug 
will be administered. The subjects should infusing study drug the same day.  Placebo 
treated patients will receive identical-looking injections with no active ingredients. 
After randomization, the Investigator will: 
 Administer study drug 
 Assess for adverse events (AE) 
 Assess changes in concomitant medication use 
 Assess for outcomes 
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Subjects will return for visits at week 0,2,6 and then every 4 weeks during the 
double-blind period. (Additional interim visits may be scheduled, at the 
Investigators discretion, if necessary) 
 
During these visits: 
 Adverse events should be recorded 
 Efficacy endpoints events should be assessed 
 Study  drug should be infused, as needed  
 Unused study drug injections should be counted 
 Targeted concomitant medications should be recorded 




In addition, clinical assessment of disease activity, hematology, and clinical 
laboratory tests would be conducted at weeks 8, 16, 22, 30, and 52 Disease 
activity was assessed using HSSI, static Physician Global Assessment (PGA) 
tool, the Dermatology Life Quality Index (DLQI), VAS, and the change in the 
number of daily dressing changes at 1-week intervals as reported by the 
patient. The HSSI assesses a composite score of symptoms and signs ranging 
from 0 to 19, as mild (0-7), moderate (8-12), or severe ([13). The static PGA 6-
point scale assesses extent of skin involvement, and reports symptoms as 
cleared (100% improvement), excellent (75%-99% improvement), good (50%-
74% improvement), fair (25%-49% improvement), slight (1%-24% 
improvement), and worse. 
 In addition, customarily instruments such as DLQI and VAS will be used to 
assess disease activity. A daily diary card was maintained by patients and 
returned at each scheduled visit. The diary page included dates of data entry, 
the number of dressing changes during working and nonworking hours, and a 
VAS assessment of pain. 
 
Study drug discontinuation visit 
Individual subjects may prematurely discontinue study drug. Reasons for 
study drug discontinuation are safety concerns, noncompliance, and the need 
of an excluded medication or withdrawal of informed consent. 
 
 Assessment of treatment efficacy will based on HSSI, DLQI, VAS, PGA, 
erythrocyte sedimentation rate (ESR), and Creactive protein (CRP) values and 
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assessment of safety will be based on reported and observed adverse events 
(AE) and laboratory test results, which included hematology, blood chemistry, 
and vital signs. 
 
Study end visit 
 
  After the last infusion, patients returned on a monthly basis to assess time 
to relapse, defined as an increase of 40% or more of HSSI score achieved at 8 
weeks after starting IFX infusion (eg, if a patient’s baseline score of 10 
decreased to 5 after 8 weeks of treatment with IFX, the patient was assessed 
as having relapsed at an HSSI score of 7 [40% of 5 = 2, 5 1 2 = 7]). Severity of 
AE will be classified as mild (well tolerated), moderate (discomfort that 







Primary efficacy assessment 
 
The primary efficacy end point of this study will be the proportion of patients 
with a clinical response at week 8 (end of period 1), defined according to the 
Hidradenitis Suppurativa Clinical Response (HiSCR) measure as at least a 50% 
reduction from baseline in the total abscess and inflammatory-nodule count, 
with no increase in the abscess or draining-fistula count. These changes have 
been identified as clinically meaningful by patients. 
 
Secondary efficacy assessment 
 
Three secondary end points will be rank-ordered at week 8. First will be a 
total abscess and inflammatory-nodule count of 0, 1, or 2 among patients 
with Hurley stage II disease (defined as recurrent abscesses, single or 
multiple, with sinus tract formation and scarring) at baseline. Second will be 
at least a 30% reduction and at least a 1-unit reduction from baseline in the 
pain score (on a numerical rating scale of the patient’s global assessment of 
skin pain, with 0 indicating no pain and 10 indicating the worst pain 
imaginable), on the basis of 24-hour recall of the worst pain, among patients 
with a baseline score of 3 or higher. Third will be the change from baseline in 
the modified Sartorius score (a score of 4 indicates the least severe disease, 
and higher scores [no upper limit] indicate increasingly severe disease). 
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Additional, non-ranked secondary outcome measures will be also assessed at 
each visit in each period. 
 Adverse events that may emerge during treatment will be monitored 
throughout the studies until 70 days after discontinuation of the study drug. 
Clinical laboratory measurements, assessment of vital signs, and physical 
examinations will be also performed. Bacteriologic culturing is not a routine 
diagnostic test for Hidradenitis  







 If patients present at screening with signs and symptoms of cellulitis, 
appropriate therapy will to be initiated as specified in the study protocol.  
 For mild cellulitis without fever and constitutional symptoms, the site 
would be cultured and oral antibiotic treatment initiated at a dose 
and for a period determined by the investigator.  
 For severe cellulitis, patients would be hospitalized and treatment 
determined by the investigator, including intravenous antimicrobial 
therapy. This same treatment protocol would be initiated if patients 
present with cellulitis during the study except that trial drug would be 





The primary efficacy end point will be the proportion of patients with a clinical 
response at week 8 (end of period 1), defined according to the Hidradenitis 
Suppurativa Clinical Response (HiSCR) measure as at least a 50% reduction from 
baseline in the total abscess and inflammatory-nodule count, with no increase in the 
abscess or draining-fistula count; these changes will be identified as clinically 
meaningful by patients.  
Three secondary end points will be rank-ordered at week 12. First would be a total 
abscess and inflammatory-nodule count of 0, 1, or 2 among patients with Hurley 
stage II disease (defined as recurrent abscesses, single or multiple, with sinus tract 
formation and scarring) at baseline. Second will be at least a 30% reduction and at 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:07:35 EET - 137.108.70.7
MASTER THESIS ΔΑΛΑΜΠΟΥΡΑ ΔΕΣΠΟΙΝΑ Σελίδα 22 
 
least a 1-unit reduction from baseline in the pain score (on a numerical rating scale 
of the patient’s global assessment of skin pain, with 0 indicating no pain and 10 
indicating the worst pain imaginable), on the basis of 24-hour recall of the worst 
pain, among patients with a baseline score of 3 or higher. Third will be the change 
from baseline in the modified Sartorius score a score of 4 indicates the least severe 
disease, and higher scores [no upper limit] indicate increasingly severe disease). 
Additional, non-ranked secondary outcome measures will be  assessed at each visit 
in each period; outcomes in period 1 for all non-ranked secondary end points are 
provided in the Supplementary Appendix. All period 1 assessments were also 
performed in period 2. Adverse events that emerged during treatment will be 
monitored throughout the studies until 70 days after discontinuation of the study 
drug. Clinical laboratory measurements, assessment of vital signs, and physical 





An adverse event (AE) is defined as nay new untoward medical occurance or 
worsening of a pre-existing medical condition in a subject or clinical investigation 
subject administered an investigational (medicinal) product and that does not 
necessarily have a causal relationship with the treatment. An AE can therefore be 
any unfavorable and unintended sign (including an abnormal laboratory finding, for 
example), symptom, or disease temporally associated with the use of investigational 
product, whether or not considered related to the investigational product. 
Serious Adverse Events 
A seriouw AE (SAE) is any untoward medical occurrence that at any dose: 
 Results in death 
 Is life-threatening (defined as an event in which the subject was at risk of 
death at the same time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe) 
 Requires impatient hospitalization or causes prolongation of existing 
hospitalization 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly/birth defect (note: reports of congenital 
anomalies/birth defects must also be reported on the Pregnancy 
Supplemental Form) 
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  Is an important medical event (defined as a medical event(s) that may not be 
immediately life-threatening  or result in death or hospitalization but, based 
upon appropriate medical and scientific judgment, may jeopardize the 
subject or may require intervention (e.g. medical, surgical) to prevent one of 
the other serious outcomes listed in the definition above.) Examples of such 
events include, but are not limited to, intensive treatment in an emergency 
room or at home for allergic bronchospasm; blood dyscrasias or convulsions 
that do not result in hospitalization. 
 
Severity of Adverse Event 
 Mild (Grande1)- Awareness of event but easily tolerated 
 Moderate(Grande 2)-Discomfort enough to cause some interference with 
usual activity 
 Severe(Grande 3)- Inability to carry out usual activity 
 Very severe(Grande 4)- Life-threatening or disabling AE 
Collection and reporting 
Adverse events can be spontaneously reported or elicited during open-ended 
questioning, examination, or evaluation of a subject. (In order to prevent 
reporting bias, subjects should not be questioned regarding the specific 
occurrence of one or more AEs) 
If known, the diagnosis of the underlying illness or disorder should be recorded, 
rather than its individual symptoms. The following information should be 
captured for all AEs: onset, duration, intensity, seriousness, relationship to 
investigational product, and action taken. The investigator shall supply the 
sponsor and Ethics Committee with any additional requested information, 
notably for reported deaths of subjects.  
Completion of supplemental CRFs may be requested for AEs and/or laboratory 
abnormalities that are reported/ identified during the course of the study. 
Following the subject’s written consent to participate in the study, all SAEs must 
be collected, including those thought to be associated with clinical study 
procedures. All SAEs must be collected which occur within 30 days of 
discontinuation of dosing with double-blind study drug. All SAEs must be 
followed until resolution. In addition, the Investigator should notify BMS of any 
SAE which may occur after this time period which they believe to be certainly 
probably or possibly related to investigational product. 
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Serious adverse events, whether related or unrelated to investigational product, 
must be recorded on the SAE page of the CRF and reported expeditiously to BMS 
(or designee) to comply with regulatory requirements. An SAE report should be 
completed for any event where doubt exists regarding its status of seriousness. 
If the Investigator believes that an SAE is not related to the investigational 
product, but is potentially related to the conditions of the study (such as 
withdrawal of previous therapy, or a complication of a study procedure), the 
relationship should be specified in the narrative section of the SAE page of the 
CRF. Moreover, if an ongoing SAE changes in its intensity or relationship to the 
investigational product, a follow-up SAE report should be sent immediately to 
the sponsor. As follow-up information becomes available it should be sent 
immediately using the same procedure used for transmitting the initial SAE 
report. Supporting documentation such as hospital discharge summaries and 
autopsy reports should be forwarded to BMS in the same manner. All SAEs 
should be followed to resolution or stabilization. 
 
Overdose 
Overdose is defined as the accidental or intentional ingestion of any dose of a 
product that is considered both excessive and medically important. All occurrences 





Compliance with the Protocol and Protocol Revisions 
The study shall be conducted as described in this approved protocol. All revisions to 
the protocol must be discussed with, and be prepared by, BMS. The Investigator 
should not implement any deviation or change to the protocol without prior view 
and documented approval/favorable opinion from the IRB/IEC of an amendment, 
except where necessary to eliminate an immediate hazard(s) to study subjects. Any 
significant deviation must be documented in the CRF. 
Records Retention 
The Investigator must retain investigational product disposition records, copies of 
CRFs (or electronic files), and source documents for the maximum period required by 
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applicable regulations and guidelines, or institution procedures or for the period 
specified by the sponsor, whichever is longer. The Investigator must contact BMS 
prior to destroying any records associated with the study. BMS will notify the 
Investigator when the study records are no longer needed. If the Investigator 
withdraws from the study (e.g. relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (e.g. another Investigator, IRB). 
Notice of such transfer will be given in writing to BMS.  
Case Report Forms 
An Investigator is required to prepare and maintain adequate and accurate case 
histories designed to record all observations and other data pertinent to the 
investigation on each individual treated or entered as a control in the investigation. 
Data reported on the CRF that are derived from source documents must be 
consistent with the source documents or the discrepancies must be explained.  
The confidentiality of records that could identify subjects must be protected, 
respecting the privacy and confidentiality entries and/or corrections on CRFs. 
The completed CRF, including any paper SAE/pregnancy CRFs, must be promptly 
reviewed, signed, and dated by a qualified physician who is an investigator or 
subinvestigator. For electronic CRFs, review and approval/ signature is completed 
electronically through the BMS electronic data capture tool. The Investigator must 
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LIST OF ABBREVIATIONS 
 
AE: adverse event  
CRP: C-reactive protein 
 DLQI: Dermatology Life Quality Index  
ESR: erythrocyte sedimentation rate  
HS: hidradenitis suppurativa  
HSSI: Hidradenitis Suppurativa Severity Index  
PGA: Physician Global Assessment  
TNF: tumor necrosis factor 
 VAS: visual analog scale 
AE: Adverse Event 
CEC: Clinical Endpoint Committee 
CRF: Case Report Form 
DMC: Data Monitoring Committee 
GCP: Good Clinical Practice 
ICH: International Conference of Harmonization 
IVRS: Interactive Voice Response System 
SAE: Serious Adverse Event 
IFX: Infliximab 
QoF : Quality of Life 
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